Overview
flowchart TD
companies_relmada["Relmada Therapeutics"]
style companies_relmada fill:#4fc3f7,stroke:#333,color:#000
companies_relmada_0["Company Profile"]
companies_relmada -->|"includes"| companies_relmada_0
style companies_relmada_0 fill:#81c784,stroke:#333,color:#000
companies_relmada_1["Funding History"]
companies_relmada -->|"includes"| companies_relmada_1
style companies_relmada_1 fill:#ef5350,stroke:#333,color:#000
companies_relmada_2["Pipeline and Products"]
companies_relmada -->|"includes"| companies_relmada_2
style companies_relmada_2 fill:#ffd54f,stroke:#333,color:#000
companies_relmada_3["Lead Candidate: REL-1017 Esmethadone"]
companies_relmada -->|"includes"| companies_relmada_3
style companies_relmada_3 fill:#ce93d8,stroke:#333,color:#000
companies_relmada_4["Research Programs"]
companies_relmada -->|"includes"| companies_relmada_4
style companies_relmada_4 fill:#4fc3f7,stroke:#333,color:#000
companies_relmada_5["Mechanism of Action"]
companies_relmada -->|"includes"| companies_relmada_5
style companies_relmada_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biotechnology company headquartered in New York, NY, focused on developing novel therapies for diseases of the central nervous system (CNS). The company's lead product candidate, REL-1017 (esmethadone), is a proprietary D-isomer of racemic methadone being developed as a treatment for major depressive disorder (MDD) and potentially other CNS indications, including [Alzheimer's disease](/diseases/alzheimers-disease)-associated depression and neuropathic pain["@relmada"].
Unlike traditional antidepressants, REL-1017 acts through a unique dual mechanism involving [NMDA receptor](/entities/nmda-receptor) modulation and sigma-1 receptor agonism, offering potential advantages over existing treatments including faster onset of action and improved tolerability.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | New York, NY |
| Founded | 2011 |
| IPO | 2017 (NASDAQ: RLMD) |
| CEO | Dr. Sergio Traversa |
| Employees | ~50-100 |
| Focus | CNS therapeutics, NMDA modulation |
Funding History
| Round | Year | Amount | Notes |
|-------|------|--------|-------|
| Series A | 2012 | $15M | Initial development |
| Series B | 2014 | $25M | Pre-IPO funding |
| IPO | 2017 | $40M | NASDAQ: RLMD |
| Post-IPO | 2020-2024 | $50M+ | Clinical development |
Pipeline and Products
Lead Candidate: REL-1017 (Esmethadone)
REL-1017 (esmethadone) is the D-isomer of racemic methadone, designed to provide NMDA receptor antagonist activity without the traditional opioid effects associated with the racemate. This selectivity allows for potentially therapeutic effects on mood and cognition while minimizing abuse potential and respiratory depression[@pmcid001].
| Attribute | Details |
|-----------|---------|
| Indication | Major Depressive Disorder (primary), Alzheimer's depression (exploratory) |
| Mechanism | NMDA receptor antagonist + sigma-1 receptor agonist |
| Route | Oral |
| Stage | Phase 3 completed (MDD), Phase 2 ongoing |
| Status | Active development; NDA filing anticipated |
Research Programs
| Program | Indication | Stage | Status |
|---------|------------|-------|--------|
| REL-1017 | Major Depressive Disorder | Phase 3 | Completed; results positive |
| REL-1017 | Alzheimer's depression | Phase 2 | Recruiting |
| REL-102 | Chronic neuropathic pain | Phase 2 | Completed |
| REL-1017 | Parkinson's disease depression | Preclinical | Exploring |
Mechanism of Action
NMDA Receptor Modulation
REL-1017 acts as a selective NMDA receptor antagonist, similar in mechanism to ketamine but without the dissociative side effects. The NMDA receptor plays a critical role in synaptic plasticity, learning, and memory — processes that are dysregulated in both depression and neurodegenerative diseases. By modulating this receptor, REL-1017 may restore proper glutamatergic signaling[@pmcid001].
Sigma-1 Receptor Agonism
The sigma-1 receptor is a chaperone protein located on the endoplasmic reticulum that regulates calcium homeostasis and mitochondrial function. Sigma-1 receptor agonism has been associated with neuroprotective effects, including:
- Reduction of oxidative stress
- Anti-apoptotic signaling
- Enhanced autophagy
- Mitochondrial protection
These mechanisms are particularly relevant to [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions where mitochondrial dysfunction and oxidative stress play key pathogenic roles[@pmcid002].
Clinical Trial Results
Phase 3 trials for REL-1017 in major depressive disorder demonstrated:
- Rapid onset of antidepressant effects (within 1-2 weeks)
- Statistically significant improvement in MADRS scores vs. placebo
- Favorable safety and tolerability profile
- No dissociative effects observed (unlike ketamine)
- Low abuse potential in controlled studies
Relevance to Neurodegeneration
While Relmada's primary focus is major depressive disorder, the company's research has implications for neurodegenerative diseases:
Alzheimer's Disease-Associated Depression
Depression is common in [Alzheimer's disease](/diseases/alzheimers-disease), affecting up to 40% of patients. REL-1017's dual mechanism (NMDA antagonism + sigma-1 agonism) may address both mood symptoms and potentially modify disease progression through neuroprotective pathways. Relmada has initiated Phase 2 studies specifically targeting this patient population.
Parkinson's Disease Depression
Depression affects approximately 50% of Parkinson's disease patients and significantly impacts quality of life. The NMDA modulator approach may provide therapeutic benefits while addressing underlying neurochemical imbalances.
- Stock Exchange: NASDAQ
- Ticker: RLMD
- Market Cap: ~$200-400M (as of 2024)
- Cash Position: Sufficient funding through 2025 clinical milestones
- Analyst Coverage: Several Wall Street firms track RLMD
Competitive Landscape
REL-1017 competes with:
- Generic NMDA antagonists (ketamine, dextromethorphan combinations)
- SSRIs/SNRIs (standard of care for depression)
- Novel glutamatergic agents (axsome, etc.)
- Esketamine formulations (J&J Spravato)
REL-1017's advantage lies in its oral delivery, non-dissociative mechanism, and proprietary D-isomer formulation.
External Links
- [Relmada Website](https://www.relmada.com/)
- [ClinicalTrials.gov - REL-1017](https://clinicaltrials.gov/search?cond=depression&intr=REL-1017)
- [NASDAQ: RLMD](https://www.nasdaq.com/market-activity/stocks/rlmd)
References
[Relmada Therapeutics Official Website](https://www.relmada.com/)
[REL-1017 Clinical Development](https://clinicaltrials.gov)
[Esmethadone (REL-1017) as a rapid-acting antidepressant (2024)](https://pubmed.ncbi.nlm.nih.gov/38594701/)
[Sigma-1 receptor and neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/36720687/)